華為及中興通訊競投泰國最大電訊商納5G網絡項目
泰國最大流動通訊商Advanced Info Service(AIS)表示,華為是競投5G核心網絡項目的5間公司之一。此前泰國稱,不會將中國供應商排除在5G基礎設施建設之外,但會留意任何安全問題。
AIS在挑選5G設備供應商已經進入最後階段,有份競投的還包括愛立信、諾基亞、中興通訊(00762.HK)及三星。
AIS計劃今年在基礎設施上花費高達450億泰銖(約14.2億美元),並計劃本月在曼谷及工業中心東部經濟走廊建設第一個5G核心網絡。
AIS上周宣布與華為成為合作夥伴,銷售華為的5G智能手機。公司重申,美國未有證據證明有關華為從事間諜活動的指控,公司將通過條款來防範中國供應商帶來的潛在安全隱患。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.